| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 10,562 | 9,464 | 8,419 | 7,886 | 7,780 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 10,562 | 9,464 | 8,419 | 7,886 | 7,780 |
Other Operating Income | 166 | 156 | 89 | 119 | 159 |
Other Income | 146 | 45 | 197 | 57 | 122 |
Total Income | 10,874 | 9,665 | 8,705 | 8,062 | 8,061 |
Total Expenditure | 7,360 | 6,778 | 6,562 | 5,520 | 5,769 |
PBIDT | 3,514 | 2,887 | 2,143 | 2,542 | 2,292 |
Interest | 354 | 333 | 255 | 358 | 451 |
PBDT | 3,160 | 2,554 | 1,888 | 2,184 | 1,841 |
Depreciation | 808 | 707 | 662 | 658 | 654 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 462 | 374 | 342 | 327 | 274 |
Deferred Tax | 234 | 228 | 107 | -53 | -112 |
Reported Profit After Tax | 1,656 | 1,245 | 777 | 1,252 | 1,025 |
Minority Interest After NP | 0 | 0 | 0 | 0 | 0 |
Net Profit after Minority Interest | 1,656 | 1,245 | 777 | 1,252 | 1,025 |
Extra-ordinary Items | 61.96 | 0 | -307.38 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 1,594.04 | 1,245 | 1,084.38 | 1,252 | 1,025 |
EPS (Unit Curr.) | 48.94 | 36.79 | 45.93 | 73.98 | 60.55 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 560 | 440 | 960 | 700 | 640 |
Equity | 169.23 | 169.23 | 84.62 | 84.62 | 84.62 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 33.27 | 30.5 | 25.45 | 32.23 | 29.46 |
PBDTM(%) | 29.91 | 26.98 | 22.42 | 27.69 | 23.66 |
PATM(%) | 15.67 | 13.15 | 9.22 | 15.87 | 13.17 |
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
Here are some of the stocks that may see significant price movement today: Hindustan Unilever, Bajaj Finance, Vedanta, etc.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
